Contineum Therapeutics (CTNM) EBIT (2023 - 2026)

Contineum Therapeutics' EBIT history runs 4 years deep, the most recent figure standing at -$16.9 million for Q1 2026.

• In Q1 2026, EBIT rose 6.66% year-over-year to -$16.9 million; the TTM figure through Mar 2026 stood at -$66.9 million (down 13.17% YoY), while the FY2025 annual figure was -$68.1 million, down 33.73% from the prior year.
• EBIT was -$16.9 million for Q1 2026 at Contineum Therapeutics, up from -$17.1 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $38.9 million in Q2 2023 to a low of -$20.9 million in Q4 2023.
• Historically, EBIT has averaged -$10.1 million across 4 years, with a median of -$14.9 million in 2025.
• Biggest YoY gain for EBIT was 18.31% in 2024; the steepest drop was 128.11% in 2024.
• A 4-year view of EBIT shows it stood at -$20.9 million in 2023, then increased by 18.31% to -$17.0 million in 2024, then declined by 0.4% to -$17.1 million in 2025, then increased by 1.23% to -$16.9 million in 2026.
• The last three EBIT figures came in at -$16.9 million (Q1 2026), -$17.1 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.